NO20052074L - Substituerte benzoksazinoner og anvendelser derav. - Google Patents

Substituerte benzoksazinoner og anvendelser derav.

Info

Publication number
NO20052074L
NO20052074L NO20052074A NO20052074A NO20052074L NO 20052074 L NO20052074 L NO 20052074L NO 20052074 A NO20052074 A NO 20052074A NO 20052074 A NO20052074 A NO 20052074A NO 20052074 L NO20052074 L NO 20052074L
Authority
NO
Norway
Prior art keywords
substituted benzoxazinones
formula
benzoxazinones
methods
provides
Prior art date
Application number
NO20052074A
Other languages
English (en)
Inventor
Shu-Hai Zhao
Hans Maag
Meng Sui
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20052074L publication Critical patent/NO20052074L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Legemiddel Substituerte benzoksazinoner og anvendelser derav. Oppfinnelsen tilveiebringer en forbindelse med formel (1): og farmasøytisk akseptable salter eller prodrug derav, hvor Y, Z, R', R'^, r\ R\ R^, R* , R^, R*, R^, m, n, p og q er som definert her. Oppfinnelsen tilveiebringer også metoder for fremstilling av, preparater omfattende og metoder for anvendelse av Forbindelser med formel (I).
NO20052074A 2002-11-08 2005-04-27 Substituerte benzoksazinoner og anvendelser derav. NO20052074L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42494602P 2002-11-08 2002-11-08
PCT/EP2003/012278 WO2004041792A1 (en) 2002-11-08 2003-11-04 Substituted benzoxazinones and uses thereof

Publications (1)

Publication Number Publication Date
NO20052074L true NO20052074L (no) 2005-06-01

Family

ID=32312902

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052074A NO20052074L (no) 2002-11-08 2005-04-27 Substituerte benzoksazinoner og anvendelser derav.

Country Status (28)

Country Link
US (1) US7141562B2 (no)
EP (1) EP1562918B1 (no)
JP (1) JP4401297B2 (no)
KR (1) KR100683361B1 (no)
CN (1) CN100390157C (no)
AR (1) AR042002A1 (no)
AT (1) ATE384054T1 (no)
AU (1) AU2003293653B2 (no)
BR (1) BR0315302A (no)
CA (1) CA2505334A1 (no)
DE (1) DE60318733T2 (no)
DK (1) DK1562918T3 (no)
ES (1) ES2298609T3 (no)
GT (1) GT200300241A (no)
HR (1) HRP20050390A2 (no)
IL (1) IL168343A (no)
MX (1) MXPA05004758A (no)
MY (1) MY136824A (no)
NO (1) NO20052074L (no)
NZ (1) NZ539508A (no)
PA (1) PA8587501A1 (no)
PE (1) PE20040828A1 (no)
PL (1) PL377770A1 (no)
PT (1) PT1562918E (no)
RU (1) RU2328490C2 (no)
TW (1) TWI285639B (no)
WO (1) WO2004041792A1 (no)
ZA (1) ZA200503248B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
AR039127A1 (es) 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
NZ544331A (en) 2003-07-22 2010-03-26 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
AU2004299201B2 (en) * 2003-12-09 2009-12-03 F. Hoffmann-La Roche Ag Benzoxazine derivatives and uses thereof
EP1799306B1 (en) * 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CN101263136A (zh) * 2005-07-13 2008-09-10 弗·哈夫曼-拉罗切有限公司 作为5-ht6、5-ht24的苯并咪唑衍生物
JP2009514795A (ja) * 2005-09-15 2009-04-09 コリア リサーチ インスティテュート オブ ケミカル テクノロジー Ｎ−置換−１ｈ−キノリン−２，４−ジオン化合物、その製造方法及びそれを含む薬学的組成物
TWI385161B (zh) * 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
ITMI20131782A1 (it) * 2013-10-25 2015-04-26 Dipharma Francis Srl Procedimento per la preparazione di un agonista della trombopoietina
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
CN108472285A (zh) 2015-07-15 2018-08-31 阿速万科学有限责任公司 用于预防和治疗与神经退行性疾病相关联的幻觉的二芳基和芳基杂芳基脲衍生物
RU2624978C2 (ru) * 2015-07-27 2017-07-11 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ лечения умеренного когнитивного снижения
SG11202000833YA (en) * 2017-08-07 2020-02-27 Suven Life Sciences Ltd Fluoropiperidine compounds as pure 5-ht6 receptor antagonists
CN111559990B (zh) * 2020-05-29 2021-03-09 四川大学华西医院 一种小分子噁噻嗪类衍生物及其应用
CN112047898A (zh) * 2020-10-14 2020-12-08 兰州大学 一种苯并[c][1,2]噁嗪骨架类新化合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU784769A3 (ru) * 1977-03-17 1980-11-30 Шел Интернэшнл Рисерч Маатсхаппии Б.В. (Фирма) Способ получени бензоксазинкарбоксамидов
ATE81975T1 (de) * 1984-12-21 1992-11-15 Duphar Int Res Arzneimittel mit psychotroper wirkung.
AU605304B2 (en) * 1987-06-22 1991-01-10 Nihon Tokushu Nayaku Seizo K.K. Benzo-fused cyclic compounds
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5955470A (en) * 1991-06-11 1999-09-21 Merrell Pharmaceuticals, Inc. Derivatives of amide analogs of certain methano bridged quinolizines
PT889889E (pt) * 1996-03-29 2007-01-31 Duphar Int Res Composto de piperazina e piperidina
DE69819266T2 (de) * 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
NZ517900A (en) * 1999-08-23 2003-08-29 Solvay Pharm Bv Phenylpiperazines useful as serotonin reuptake inhibitors
EP1255743A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. 3,4-DIHYDRO-2H-BENZO[1,4]OXAZINE INHIBITORS OF FACTOR Xa
EP1268452A1 (en) 2000-03-24 2003-01-02 Millenium Pharmaceuticals, Inc. BICYCLIC SULFONYL AMINO INHIBITORS OF FACTOR Xa
DE10031391A1 (de) 2000-07-03 2002-02-07 Knoll Ag Bicyclische Verbindungen und ihre Verwendung zur Prophylaxe und Therapie der zerebralen Ischämie
US6939871B2 (en) * 2000-10-26 2005-09-06 Smithkline Beecham P.L.C. Benzoxazinone derivatives, their preparation and use
RU2268884C2 (ru) * 2001-08-10 2006-01-27 Ф.Хоффманн-Ля Рош Аг Арилсульфонильные производные, обладающие сродством к рецептору 5-ht6, и способ их получения
UA76877C2 (uk) * 2002-05-13 2006-09-15 Ф.Хоффманн-Ля Рош Аг Похідні бензоксазину як 5-нт6 модулятори і їх застосування

Also Published As

Publication number Publication date
TWI285639B (en) 2007-08-21
GT200300241A (es) 2004-06-03
PE20040828A1 (es) 2004-11-25
PT1562918E (pt) 2008-03-12
KR100683361B1 (ko) 2007-02-15
WO2004041792A1 (en) 2004-05-21
DE60318733T2 (de) 2009-01-15
PL377770A1 (pl) 2006-02-20
AR042002A1 (es) 2005-06-08
EP1562918B1 (en) 2008-01-16
IL168343A (en) 2010-05-31
MXPA05004758A (es) 2005-08-02
CA2505334A1 (en) 2004-05-21
ES2298609T3 (es) 2008-05-16
TW200418846A (en) 2004-10-01
BR0315302A (pt) 2005-08-23
NZ539508A (en) 2007-05-31
RU2328490C2 (ru) 2008-07-10
KR20050072479A (ko) 2005-07-11
DE60318733D1 (de) 2008-03-06
CN100390157C (zh) 2008-05-28
RU2005117965A (ru) 2006-01-27
ZA200503248B (en) 2006-02-22
US20040092512A1 (en) 2004-05-13
MY136824A (en) 2008-11-28
CN1723205A (zh) 2006-01-18
US7141562B2 (en) 2006-11-28
EP1562918A1 (en) 2005-08-17
JP4401297B2 (ja) 2010-01-20
AU2003293653B2 (en) 2009-05-14
JP2006514615A (ja) 2006-05-11
HRP20050390A2 (en) 2006-12-31
AU2003293653A1 (en) 2004-06-07
ATE384054T1 (de) 2008-02-15
PA8587501A1 (es) 2004-05-26
DK1562918T3 (da) 2008-05-05

Similar Documents

Publication Publication Date Title
NO20083434L (no) Benzamid- og heteroarenderivater
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
WO2006005609A3 (de) Substituierte oxindol-derivate und diese enthaltende arzneimittel
DK1029853T3 (da) Heteroaromatiske bicykliske derivativer, der er egnede som anticancermidler
WO2007084728A3 (en) 2-imino-benzimidazoles
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
WO2003082205A3 (en) Compounds and methods
NO20015172L (no) 1-metyl-erytromycin-derivater
MY139612A (en) Benzoxazine derivatives as 5-th6 modulators and uses thereof
NO20040881L (no) Orale antidiabetes midler.
DK1181299T3 (da) C-2-modificerede erythromycinderivater
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
MY136824A (en) Substituted benzoxazinones and uses thereof
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
MXPA05011176A (es) Derivados de carboxamida como agentes antidiabeticos.
NO20062491L (no) Benzoksazinderivter og deres anvendelse
MY138826A (en) 2,7-substituted indoles
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
MXPA04006041A (es) Antivirales de piridoquinoxalina.
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
WO2004014389A8 (en) 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
NO20071616L (no) Benzoksazin- og kinoksalinderivater og anvendelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application